China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
CANTON, Mass., Sept. 07, 2016 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at BioCentury’s 23rd Annual NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016 at 10:30 a.m. Eastern Time. The conference will be held at Millennium Broadway Hotel, 145 West 44th Street, New York, NY.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
For Important Safety Information Visit, http://www.xtampzaer.com/
Contact: Douglas Carlson Vice President, Corporate Development [email protected]
